Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System

2014-08-27 03:13:46 | BioPortfolio


The QuickClose Design 9 is a prospective, non randomized study, to evaluate the safety and efficacy of the QuickClose design 9 closure device.

patient undergoing a diagnostic or therapeutic angiogram procedure will be treated with the QuickClose Design 9. Patients will be monitored until 30 days after the procedure.


the primary safety endpoint is the incidence of major complications related to method for achieving hemostasis at the puncture site. the secondary safety endpoints is the incidence of minor complications related to method for achieving hemostasis at the puncture site. the primary efficacy endpoints are time to hemostasis, time to ambulation and time to discharge. the secondary efficacy endpoints are device and procedure success

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care




closure device


Heart Institute Sheba medical center
Tel Hashomer





Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:13:46-0400

Clinical Trials [894 Associated Clinical Trials listed on BioPortfolio]

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology

The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects wi...

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high ...

Patient Comfort With Vascular Closure

The purpose of this research study is to collect information on the amount of discomfort patients experience with one of two different vascular blood vessel closure devices, the MynxM5 Vas...

Evaluating Outcomes in the Placement of Boomerang Percutaneous Device

The purpose of this study is to evaluate the safety and effectiveness of the Boomerang percutaneous closure device following diagnostic cerebral angiography or neurointerventional procedur...

Comparison of Adhesive Latch Device to Subcuticular Skin Closure at the Time of Cesarean Section

The objective of this study was to compare the an adhesive latch device (" Dermaclip") to subcuticular skin closure at the time of cesarean section. Currently, no studies exist comparing t...

PubMed Articles [3144 Associated PubMed Articles listed on BioPortfolio]

Use of a NobleStitch™ EL Device for PFO Closure.

Cryptogenic stroke is the final diagnosis in almost 40% of ischemic acute cerebrovascular events. There is currently no definitive clinical evidence that percutaneous closure of patent foramen ovale (...

Left atrial thrombus two years after placement of a left atrial appendage closure device.

A 72-year-old man who underwent a left atrial appendage (LAA) closure device two years ago, presented with atrial flutter with rapid ventricular rate and was referred for cardioversion. Pre-cardiovers...

Intraoperative Device Closure of Isolated Ventricular Septal Defects: Experience on 1090 Cases.

This study aims at summarizing the clinical experiences and 8-year follow-up results of the intraoperative device closure of ventricular septal defects.

Implementation of the EXOSEAL Vascular Closure Device in the Transpopliteal Arterial Approach.

To investigate the feasibility and safety of the EXOSEAL vascular closure device (VCD) in achieving hemostasis in transpopliteal arterial interventions.

Successful percutaneous closure of a large symptomatic AV fistula using an amplatzer occluder device.

Atrial septal device occluders such as amplatzer occluder have been designed to close atrial septal defects of paten formal ovale. Off label use of this device has been reported in pathological condit...

Medical and Biotech [MESH] Definitions

Removal of a MEDICAL DEVICE from the market due to the identification of an intrinsic property of the device that results in a serious risk to public health.

The tendency to perceive an incomplete pattern or object as complete or whole. This includes the Gestalt Law of Closure.

The coagulation of tissue by an intense beam of light, including laser (LASER COAGULATION). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, hemorrhages, and malignant and benign neoplasms. (Dictionary of Visual Science, 3d ed)

Therapeutic closure of spaces caused by the extraction of teeth, the congenital absence of teeth, or the excessive space between teeth.

Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.

More From BioPortfolio on "Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System"

Quick Search


Relevant Topic

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Searches Linking to this Trial